How to appeal an Aetna vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters

Cited policy: Aetna Clinical Policy Bulletin Carotid Artery Stenting (and CPB on Carotid Endarterectomy)

Symptomatic carotid stenosis >=50% (NASCET) OR asymptomatic >=70% with reasonable life expectancy >=5 yr. CAS reserved for high surgical risk (per CMS NCD 20.7 / SVS 2022) — anatomic, medical, prior neck RT, restenosis post-CEA. TCAR per ROADSTER pathway as alternative to transfemoral CAS.

How Aetna denies vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters — and how to counter it

Where Aetna pushes back: 1) Patient not 'high risk' for CEA; 2) Asymptomatic stenosis below threshold; 3) Neurologic symptoms not clearly correlated; 4) TCAR vs transfemoral CAS rationale.

Counter-arguments that hold up: Document high-risk anatomy (radical neck dissection, prior neck RT, contralateral laryngeal nerve palsy, contralateral occlusion, restenosis post-CEA) or medical risk. NASCET-equivalent stenosis with PSV / EDV / ICA-CCA ratio. Cite CREST 10-yr (Brott NEJM 2016) + SVS 2022 (AbuRahma JVS) + ACT-1 for asymptomatic. For TCAR cite ROADSTER 2 (Kashyap JVS 2020). Document symptom-stenosis correlation (TIA / stroke side, imaging).

What Aetna typically denies for vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters treatments most often flagged for prior auth, step therapy, or medical necessity review:

• EVAR (AAA)
• F-EVAR / B-EVAR
• Open AAA repair
• TEVAR
• CEA
• CAS (transfemoral)

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.